Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2013-03-18 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Trading Halt 2 pages 56.7KB
Regulatory Filings Classification · 95% confidence The document is a market release dated 19 March 2013 from Pharmaxis Ltd requesting a trading halt on its securities pending the release of an announcement related to a Complete Response Letter from the FDA regarding a New Drug Application. The text is short (2206 characters) and primarily serves as a notification to the stock exchange and investors about the trading halt and the reason for it. There is no financial data, report content, or detailed analysis present. This is an announcement about a trading halt, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance-related notices that do not fit other categories.
2013-03-18 English
PHARMAXIS RECEIVES COMPLETE RESPONSE LETTER FROM FDA 2 pages 107.4KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 19 March 2013 from Pharmaxis Ltd announcing that the FDA has issued a complete response letter regarding the Bronchitol New Drug Application (NDA). It discusses the FDA's decision, the need for additional clinical trials, and the company's plans to engage further with the FDA. The document is a public announcement about regulatory feedback and next steps rather than a detailed financial report, earnings release, or any form of regulatory filing like an annual report or audit report. It does not contain financial data or detailed management discussion but is a communication about regulatory status and company plans. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2013-03-18 English
Pharmaxis Appoints Gary Phillips New Chief Executive Officer 3 pages 118.8KB
Board/Management Information Classification · 95% confidence The document is a media release announcing the appointment of a new Chief Executive Officer at Pharmaxis. It discusses business strategy, FDA regulatory expectations, clinical trial progress, sales growth, and pipeline assets. There are no financial statements, detailed financial performance data, or comprehensive management discussion typical of annual or interim reports. The document focuses on management changes and strategic updates rather than financial results or regulatory filings. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes in senior management.
2013-03-11 English
Final Director's Interest Notice 2 pages 12.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including ordinary shares and options, and notes the date the director ceased to be a director. This is a report of personal share transactions or holdings by a company director, which fits the definition of Director's Dealing filings. The document length is short and focused solely on director share interests, with no financial statements or other report content. Therefore, the correct classification is Director's Dealing (DIRS).
2013-03-11 English
Initial Director's Interest Notice 2 pages 68.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including ordinary shares and options, and notes the director's appointment date. The content is focused on reporting personal share transactions or holdings by a company director. The document length is short (2187 characters) and it is a formal notice of director's interests in securities. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). Therefore, the correct classification is DIRS.
2013-03-11 English
Bronchiectasis Phase 3 Trial Milestone 2 pages 97.4KB
Capital/Financing Update Classification · 85% confidence The document is an ASX media release dated 8 March 2013 announcing the formal completion of a Phase 3 clinical trial for Bronchitol in bronchiectasis patients. It provides details about the trial design, endpoints, and potential regulatory implications. The document is a public announcement of a clinical trial milestone and does not contain financial statements, management discussion, or detailed financial data. It is not a report such as an Annual Report, Interim Report, or Earnings Release. It is also not a regulatory filing, board change, or voting result. The content fits best as a Capital/Financing Update (CAP) because it relates to a significant development in the company's product pipeline that could impact future financing or market position, typical of pharmaceutical company announcements about clinical trial progress. The document length (5660 characters) and content confirm it is a full announcement rather than a brief notice or report publication announcement.
2013-03-07 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.